* Bicycle Therapeutics PLC BCYC.OQ reported a quarterly
adjusted
loss of 62 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-1.30. The mean expectation of eleven analysts
for the quarter was for a loss of $1.24 per share. Wall Street
expected results to range from $-1.40 to $-1.03 per share.
* Revenue rose 298.9% to $19.53 million from a year ago;
analysts
expected $6.03 million.
* Bicycle Therapeutics PLC's reported EPS for the quarter
was a
loss of 62 cents.
* The company reported a quarterly loss of $26.56 million.
* Bicycle Therapeutics PLC shares had fallen by 2.8% this
quarter and gained 33.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is $41.50
This summary was machine generated from LSEG data May 2 at 05:04
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.24 -0.62 Beat
Dec. 31 2023 -1.23 -1.16 Beat
Sep. 30 2023 -1.17 -1.26 Missed
Jun. 30 2023 -1.29 -1.41 Missed